Haemorragic and thromboembolic risk in CKD patients with non valvular atrial fibrillation: Do we need a novel risk score calculator?


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
01 Jan 2019
Historique:
received: 10 06 2018
revised: 08 07 2018
accepted: 12 07 2018
pubmed: 5 9 2018
medline: 25 7 2019
entrez: 5 9 2018
Statut: ppublish

Résumé

Non valvular atrial fibrillation (NVAF) is highly prevalent among chronic kidney disease (CKD) patients in whom it portends increased risk for subsequent stroke or systemic thromboembolic events. For these high risk patients oral anticoagulation is recommended, after proper assessment of both thromboembolic and bleeding risk is accurately ascertained. However, current NVAF risk scores are inadequate for use in CKD subjects, since they do not take into account the occurrence and the degree of renal function impairment. Aim of this review was therefore to provide the reader with an analytical review of each risk factor included in the available risk scores systems, as well as the evaluation of the accuracy of currently adopted score systems for either bleeding or ischemic event risk prediction in patients with CKD. On the basis of available data from literature, reclassifying those patients categorized at low-risk, for whom the presence of renal impairment may be the only predictor for future adverse events emerges as a compelling unmet need. Accordingly, a new risk score calculator, specific for CKD patients is also provided.

Identifiants

pubmed: 30177235
pii: S0167-5273(18)33747-1
doi: 10.1016/j.ijcard.2018.07.066
pii:
doi:

Substances chimiques

Anticoagulants 0

Types de publication

Journal Article Review

Langues

eng

Pagination

179-185

Informations de copyright

Copyright © 2018 Elsevier B.V. All rights reserved.

Auteurs

Maura Ravera (M)

Nephrology, Dialysis, and Transplantation, University of Genoa and Policlinico San Martino, Genoa, Italy. Electronic address: maura.ravera@hsanmartino.it.

Elisabetta Bussalino (E)

Nephrology, Dialysis, and Transplantation, University of Genoa and Policlinico San Martino, Genoa, Italy.

Ernesto Paoletti (E)

Nephrology, Dialysis, and Transplantation, University of Genoa and Policlinico San Martino, Genoa, Italy.

Antonio Bellasi (A)

Department of Nephrology and Dialysis, Ospedale Sant'Anna, ASST-Lariana, Como, Italy.

Luca Di Lullo (L)

Department of Nephrology and Dialysis, Parodi-Delfino Hospital, Colleferro, Italy.

Maria Fusaro (M)

National Research Council (CNR), Institute of Clinical Physiology (IFC), Pisa, Italy, Department of Medicine, University of Padova, Italy. Electronic address: dante.lucia@libero.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH